title: Effects of ferulic acid on diabetic nephropathy in a rat model of type 2 diabetes.
abstract: Diabetic nephropathy is the most serious complication in diabetes mellitus. It is known that oxidative stress and inflammation play a central role in the development of diabetic nephropathy. In this study, we investigated that ferulic acid (FA) known as anti-oxidative agent could effect on diabetic nephropathy by anti-oxidative and anti-inflammatory mechanism. We examined the effects of FA in obese diabetic Otsuka Long-Evans Tokushima Fatty (OLETF) rats and non-diabetic control Long-Evans Tokushima Otsuka (LETO) rats. We treated FA to experimental rats from 26 to 45 weeks of age. We evaluated ACR, MDA and MCP-1 in 24 h urine and examined renal histopathology and morphologic change in extracted kidneys from rats. Also, we evaluated the ROS production and MCP-1 levels in cultured podocyte after FA treatment. In the FA-treated OLETF rats, blood glucose was significantly decreased and serum adiponectin levels were increased. Urinary ACR was significantly reduced in FA-treated OLETF rats compared with diabetic OLETF rats. In renal histopathology, FA-treated OLETF rats showed decreased glomerular basement membrane thickness, glomerular volume, and mesangial matrix expansion. FA treatment decreased oxidative stress markers and MCP-1 levels in 24 h urine of rats and supernatants of cultured podocyte. In conclusion, it was suggested that FA have protective and therapeutic effects on diabetic nephropathy by reducing oxidative stress and inflammation.
authors.affiliation: Department of Internal Medicine Yonsei University Wonju College of Medicine Wonju 220-701, Korea.
authors.forename: Ran
authors.initials: R
authors.lastname: Choi
authors.forename: Bo Hwan
authors.initials: BH
authors.lastname: Kim
authors.forename: Jarinyaporn
authors.initials: J
authors.lastname: Naowaboot
authors.forename: Mi Young
authors.initials: MY
authors.lastname: Lee
authors.forename: Mi Ri
authors.initials: MR
authors.lastname: Hyun
authors.forename: Eun Ju
authors.initials: EJ
authors.lastname: Cho
authors.forename: Eun Soo
authors.initials: ES
authors.lastname: Lee
authors.forename: Eun Young
authors.initials: EY
authors.lastname: Lee
authors.forename: Young Chul
authors.initials: YC
authors.lastname: Yang
authors.forename: Choon Hee
authors.initials: CH
authors.lastname: Chung
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D000975:Antioxidants / Q000627:therapeutic use*; D002478:Cells, Cultured; D018932:Chemokine CCL2 / Q000235:genetics / Q000652:urine; D003094:Collagen / Q000032:analysis; D003373:Coumaric Acids / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D003928:Diabetic Nephropathies / Q000150:complications* / Q000188:drug therapy* / Q000473:pathology; D015870:Gene Expression / Q000187:drug effects; D007668:Kidney / Q000187:drug effects / Q000473:pathology; D008315:Malondialdehyde / Q000652:urine; D050199:Podocytes / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D020334:Rats, Inbred OLETF; D017382:Reactive Oxygen Species / Q000378:metabolism; D053773:Transforming Growth Factor beta1 / Q000032:analysis
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000975:Antioxidants; C491766:Ccl2 protein, rat; D018932:Chemokine CCL2; D003373:Coumaric Acids; D017382:Reactive Oxygen Species; D053773:Transforming Growth Factor beta1; D008315:Malondialdehyde; D003094:Collagen; C004999:ferulic acid